Compare · GYRE vs NVO
GYRE vs NVO
Side-by-side comparison of Gyre Therapeutics Inc. (GYRE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GYRE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 312.0x GYRE ($587.0M).
- NVO has been more active in the news (8 items in the past 4 weeks vs 7 for GYRE).
- NVO has more recent analyst coverage (25 ratings vs 3 for GYRE).
- Company
- Gyre Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $6.05-4.12%
- $41.01-4.51%
- Market cap
- $587.0M
- $183.15B
- 1M return
- -14.37%
- -
- 1Y return
- -28.91%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- News (4w)
- 7
- 8
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GYRE
- Chief Operating Officer Ye Weiguo exercised 34,976 shares at a strike of $0.75 and sold $218,561 worth of shares (34,976 units at $6.25) (SEC Form 4)
- Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Operating Officer Ye Weiguo exercised 7,500 shares at a strike of $0.75 and sold $45,680 worth of shares (7,500 units at $6.09) (SEC Form 4)
- Chief Operating Officer Ye Weiguo exercised 22,220 shares at a strike of $0.75 and sold $136,653 worth of shares (22,220 units at $6.15) (SEC Form 4)
- SEC Form 4 filed by Director Zhang Ping
- Chief Operating Officer Ye Weiguo exercised 9,320 shares at a strike of $0.75 and sold $59,418 worth of shares (9,320 units at $6.38) (SEC Form 4)
- Chief Operating Officer Ye Weiguo exercised 28,680 shares at a strike of $0.75 and sold $194,773 worth of shares (28,680 units at $6.79) (SEC Form 4)
- Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care